MX2010006911A - Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina. - Google Patents

Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina.

Info

Publication number
MX2010006911A
MX2010006911A MX2010006911A MX2010006911A MX2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
dibenz0
oxepine
mineralocorticoid receptor
derived
Prior art date
Application number
MX2010006911A
Other languages
English (en)
Spanish (es)
Inventor
Prabhakar Kondaji Jadhav
Konstantinos Gavardinas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010006911(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2010006911A publication Critical patent/MX2010006911A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2010006911A 2007-12-19 2008-12-09 Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina. MX2010006911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
MX2010006911A true MX2010006911A (es) 2010-10-05

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006911A MX2010006911A (es) 2007-12-19 2008-12-09 Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina.

Country Status (33)

Country Link
US (1) US7994164B2 (https=)
EP (2) EP2235007B1 (https=)
JP (1) JP5562866B2 (https=)
KR (1) KR101254382B1 (https=)
CN (1) CN101903377B (https=)
AR (1) AR069554A1 (https=)
AU (1) AU2008343524B2 (https=)
BR (1) BRPI0820805A2 (https=)
CA (1) CA2710409C (https=)
CL (1) CL2008003600A1 (https=)
CO (1) CO6300953A2 (https=)
DK (1) DK2235007T3 (https=)
DO (1) DOP2010000185A (https=)
EA (1) EA017668B1 (https=)
EC (2) ECSP10010266A (https=)
ES (2) ES2459318T3 (https=)
GT (1) GT201000179A (https=)
HR (1) HRP20120916T1 (https=)
IL (1) IL206353A (https=)
MA (1) MA31910B1 (https=)
MX (1) MX2010006911A (https=)
MY (1) MY150474A (https=)
NZ (1) NZ586300A (https=)
PE (1) PE20091057A1 (https=)
PL (1) PL2235007T3 (https=)
PT (1) PT2235007E (https=)
RS (1) RS52594B (https=)
SI (1) SI2235007T1 (https=)
TN (1) TN2010000292A1 (https=)
TW (1) TWI431010B (https=)
UA (1) UA100131C2 (https=)
WO (1) WO2009085584A1 (https=)
ZA (1) ZA201004257B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
AU2010222902B2 (en) * 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AU2014261070A1 (en) 2013-05-02 2015-10-29 Pfizer Inc. Imidazo-triazine derivatives as PDE10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
MX367404B (es) 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
US20170246166A1 (en) * 2014-11-21 2017-08-31 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
RU2725153C1 (ru) * 2016-09-24 2020-06-30 Кбп Биосаенсес Ко., Лтд Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) * 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
US7056911B1 (en) 1999-01-26 2006-06-06 Dana-Farber Cancer Institute Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7482344B2 (en) * 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) * 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
RU2007107177A (ru) 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
CA2585797C (en) 2004-11-10 2015-01-06 Incyte Corporation Lactam compounds and their use as pharmaceuticals
SI2089367T1 (sl) 2006-10-31 2012-02-29 Pfizer Prod Inc Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev
JP2010522732A (ja) 2007-03-29 2010-07-08 ナームローゼ・フエンノートチヤツプ・オルガノン 鉱質コルチコイド受容体アンタゴニスト
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
AU2009206733A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists
AU2010222902B2 (en) 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
CO6300953A2 (es) 2011-07-21
HK1144284A1 (en) 2011-02-11
GT201000179A (es) 2012-04-16
IL206353A (en) 2014-06-30
NZ586300A (en) 2012-06-29
EP2235007A1 (en) 2010-10-06
TW200930721A (en) 2009-07-16
ECSP12012048A (es) 2012-08-31
KR20100082866A (ko) 2010-07-20
PT2235007E (pt) 2013-01-22
CL2008003600A1 (es) 2010-02-19
RS52594B (sr) 2013-04-30
AR069554A1 (es) 2010-02-03
CN101903377A (zh) 2010-12-01
JP2011507868A (ja) 2011-03-10
EA017668B1 (ru) 2013-02-28
ZA201004257B (en) 2011-11-30
CN101903377B (zh) 2014-07-09
ES2396605T3 (es) 2013-02-22
AU2008343524B2 (en) 2012-03-08
CA2710409A1 (en) 2009-07-09
MA31910B1 (fr) 2010-12-01
DOP2010000185A (es) 2010-09-15
EP2537845A1 (en) 2012-12-26
PL2235007T3 (pl) 2013-03-29
TWI431010B (zh) 2014-03-21
EP2537845B1 (en) 2014-03-19
SI2235007T1 (sl) 2013-01-31
ECSP10010266A (es) 2010-07-30
IL206353A0 (en) 2010-12-30
AU2008343524A1 (en) 2009-07-09
BRPI0820805A2 (pt) 2015-06-16
JP5562866B2 (ja) 2014-07-30
ES2459318T3 (es) 2014-05-09
WO2009085584A1 (en) 2009-07-09
UA100131C2 (uk) 2012-11-26
US7994164B2 (en) 2011-08-09
MY150474A (en) 2014-01-30
CA2710409C (en) 2012-11-06
EP2235007B1 (en) 2012-10-31
HRP20120916T1 (hr) 2012-12-31
DK2235007T3 (da) 2012-12-17
EA201070762A1 (ru) 2010-12-30
KR101254382B1 (ko) 2013-04-15
TN2010000292A1 (en) 2011-11-11
US20090163472A1 (en) 2009-06-25
PE20091057A1 (es) 2009-07-20

Similar Documents

Publication Publication Date Title
MX2010006911A (es) Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina.
UA106611C2 (uk) Інгібітори зовнішнього медулярного калієвого каналу нирок
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
EP2220074A4 (en) 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
WO2007092879A3 (en) Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
WO2007109783A3 (en) Substituted pyrimidine kinase inhibitors
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
EA201000319A1 (ru) Производные азациклилизохинолинона и изоиндолинона в качестве антагонистов гистаминовых рецепторов подтипа 3
WO2007121154A3 (en) Substituted benzothiazole kinase inhibitors
UA104867C2 (uk) Похідні феноксихроманкарбонової кислоти, заміщені в 6-ому положенні
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
MX2013004739A (es) Derivados heterociclicos de diazenodiolato.
EA201001828A1 (ru) Способ синтеза производных 3,6-дигидро-1,3,5-триазина
MX2013010270A (es) Derivados heterociclicos diazeniodiolato de amina primaria.
EA201001872A1 (ru) Новые способы получения производных циклопропиламида
WO2009145358A3 (en) Medicament for the prophylaxis or treatment of hypertension
WO2010146551A3 (en) Orally disintegrating compositions comprising antihypertensive agents
CY1113668T1 (el) Μη στεροειδεις ανταγωνιστες μεταλλoκoρτικoειδους υποδοχεα προερχομενοι απο 6η-διβενζο[β,ε]οξεπινη
MX2013008373A (es) Derivados de diazeniodiolato.
JO2827B1 (en) Mineralocorticoid receptor antagonists and methods of use
TH111703A (th) มินเนอโรคอร์ติซอยด์ รีเซปเตอร์ แอนทากอนิสท์ และวิธีการใช้

Legal Events

Date Code Title Description
FG Grant or registration